Genome-wide association studies (GWAS) have established the cyclin-dependent kinase inhibitor (CDKN)2a locus, also called INK4a/ARF, as a hotspot influencing genetic risk for cardiovascular and metabolic diseases including T2D. The gene discussed is CDKN2A; the disease is metabolic disease.